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Low LDL cholesterol, PCSK9 and HMGCR genetic variation, 
and risk of Alzheimer’s disease and Parkinson’s disease: 
Mendelian randomisation study
Marianne Benn,1,2,3 Børge G Nordestgaard,2,3,4,5  Ruth Frikke-Schmidt,1,2,3,5  Anne Tybjærg-Hansen1,2,3,5  
ABSTRACT
ObjeCtive
To test the hypothesis that low density lipoprotein 
(LDL) cholesterol due to genetic variation in the genes 
responsible for LDL cholesterol metabolism and 
biosynthesis(PCSK9 and 3-hydroxy-3-methylglutaryl-
CoA reductase (HMGCR), respectively) is associated 
with a high risk of Alzheimer’s disease, vascular 
dementia, any dementia, and Parkinson’s disease in 
the general population.
Design
Mendelian randomisation study.
setting
Copenhagen General Population Study and 
Copenhagen City Heart Study.
PartiCiPants
111 194 individuals from the Danish general population.
Main OutCOMe Measures
Risk of Alzheimer’s disease, vascular dementia, all 
dementia, and Parkinson’s disease.
results
In observational analyses, the multifactorially 
adjusted hazard ratio for Parkinson’s disease in 
participants with an LDL cholesterol level <1.8 mmol/L 
versus ≥4.0 mmol/L was 1.70 (95% confidence 
interval 1.03 to 2.79), whereas the corresponding 
hazard ratios for Alzheimer’s disease, vascular 
dementia, or any dementia did not differ from 1.0. 
PCSK9 and HMGCR variants combined were 
associated with a 9.3% lower LDL cholesterol level. In 
genetic, causal analyses adjusted for age, sex, and 
year of birth, the risk ratios for a lifelong 1 mmol/L 
lower LDL cholesterol level were 0.57 (0.27 to 1.17) for 
Alzheimer’s disease, 0.81 (0.34 to 1.89) for vascular 
dementia, 0.66 (0.34 to 1.26) for any dementia, and 
1.02 (0.26 to 4.00) for Parkinson’s disease. Summary 
level data from the International Genomics of 
Alzheimer’s Project using Egger Mendelian 
randomisation analysis gave a risk ratio for 
Alzheimer’s disease of 0.24 (0.02 to 2.79) for 26 
PCSK9 and HMGCR variants, and of 0.64 (0.52 to 0.79) 
for 380 variants of LDL cholesterol level lowering.
COnClusiOn
Low LDL cholesterol levels due to PCSK9 and HMGCR 
variants had no causal effect on high risk of 
Alzheimer’s disease, vascular dementia, any 
dementia, or Parkinson’s disease; however, low LDL 
cholesterol levels may have a causal effect in reducing 
the risk of Alzheimer’s disease.
Introduction
Inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase with statins and inhibiting pro-
protein convertase subtilisin-kexin type 9 (PCSK9) with 
monoclonal antibodies lower low density lipoprotein 
(LDL) cholesterol levels, and statins also lower the risk 
of cardiovascular disease.1-6  However, cholesterol is a 
major constituent of the myelin encircling neurons in 
the brain, and the risk of neurological diseases such as 
Alzheimer’s disease and Parkinson’s disease have been 
reported in people treated with traditional cholesterol 
lowering drugs,7  in particular statins,8 9  although 
results have been conflicting.10-13 Also, early results on 
PCSK9 inhibitors have suggested that compared with 
placebo they might increase the frequency of neurolog-
ical symptoms (evolocumab 0.9% v 0.3% and aliro-
cumab 1.2% v 0.5%), although these results were not 
statistically significant.5 6 14  Thus it is not known 
whether a low LDL cholesterol level in itself has a causal 
effect on risk of Alzheimer’s disease and Parkinson’s 
disease. This is important, as current guidelines on the 
treatment and prevention of cardiovascular disease rec-
ommend an LDL cholesterol level of less than 1.8 
mmol/L in patients at very high risk of cardiovascular 
disease and less than 2.6 mmol/L in patients at high 
risk.15
To investigate whether a low LDL cholesterol level 
has a causal effect on risk of Alzheimer’s disease, vas-
cular dementia, any dementia, and Parkinson’s dis-
ease, we used the Mendelian randomisation approach 
with variants in the genes encoding HMG-CoA reduc-
tase and PCSK9, the drug targets of statins and PCSK9 
inhibitors.16 17  Mendelian randomisation is an epidemi-
ological approach that aims to circumvent confounding 
and reverse causation by use of genetic variation in 
populations.18 19 Because of the random assortment of 
genetic variants at conception, variants with an effect 
on a modifiable exposure of interest (that is, LDL 
WhAT IS AlReAdy knoWn on ThIS TopIC
Patients at high risk of cardiovascular disease are currently recommended to lower 
their low density lipoprotein (LDL) cholesterol levels to <1.8 mmol/L
Because cholesterol is a major constituent of the brain, it has been suggested that 
low levels of LDL cholesterol might lead to increased risk of neurological diseases 
such as Alzheimer’s disease and Parkinson’s disease
WhAT ThIS STudy AddS
This study found no evidence to suggest that low LDL cholesterol levels lead to a 
high risk of developing dementia or Parkinson’s disease
Low LDL cholesterol levels, however, might have a causal effect in reducing the risk 
of Alzheimer’s disease
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 cholesterol) are randomly distributed in relation to 
most potential confounders. Also, because genetic vari-
ants are determined at conception and remain constant 
throughout life, the Mendelian randomisation design is 
not influenced by reverse causation. Thus, if a low LDL 
cholesterol level has a causal effect on risk of Alzhei-
mer’s disease, vascular dementia, any dementia, and 
Parkinson’s disease, genetic variants that lower LDL 
cholesterol levels lifelong would be expected to also 
increase the risk of disease.
Using a Mendelian randomisation design in 111 194 
individuals from two prospective general population 
studies, the Copenhagen General Population Study and 
the Copenhagen City Heart Study, we tested the hypothe-
sis that a low LDL cholesterol level due to genetic varia-
tion in PCSK9 and HMGCR is associated with a high risk 
of Alzheimer’s disease, vascular dementia, any demen-
tia, and Parkinson’s disease. We tested firstly whether 
LDL cholesterol level at baseline is associated prospec-
tively with disease (see study design supplementary fig-
ure); secondly, whether scores of LDL cholesterol 
lowering alleles of PCSK9 R46L (rs11591147), R237W 
(rs148195424), I474V (rs562556), and E670G (rs505151), 
and HMGCR (rs17238484) are associated with low LDL 
cholesterol concentrations as expected; thirdly, whether 
LDL cholesterol lowering alleles are associated directly 
with risk of diseases, as an indication of a causal effect of 
low LDL cholesterol levels on risk of disease; and 
fourthly, whether the causal effect of low LDL cholesterol 
levels is consistent with the corresponding observational 
associations using instrumental variable analysis. For 
Alzheimer’s disease, we also included a risk estimate 
using summary level data from the Global Lipid Genetics 
Consortium20  and the International Genomics of Alzhei-
mer’s Project21 on PCSK9 and HMGCR genetic variants 
combined, and finally to increase statistical power on all 
LDL cholesterol lowering variants included in the Inter-
national Genomics of Alzheimer’s Project study. The 
PCSK9 and HMGCR studies were the primary hypotheses 
and the generic score of all LDL cholesterol lowering vari-
ants used in Global Lipid Genetics Consortium/Interna-
tional Genomics of Alzheimer’s Project following a 
negative result for PCSK9 and HMGCR.
Methods
Participants
We included participants from two similar prospective 
studies of the Danish general population: the Copenha-
gen General Population Study (n=99 993) and the 
Copenhagen City Heart Study (n=11 201).22-25 Combining 
these two studies yielded a total of 111 194 participants 
of whom 1001 developed Alzheimer’s disease, 256 vas-
cular dementia, 2154 any dementia, and 460 Parkin-
son’s disease during up to 37 years of follow-up (median 
8.2 years). All participants were white and of Danish 
descent, and none were included in more than one 
study. No participants were lost to follow-up.
The Copenhagen General Population Study
The Copenhagen General Population Study was 
 initiated in 2003 and enrolment is ongoing.22 24-26 
 Participants were selected based on the national Dan-
ish civil registration system to reflect the adult white 
Danish population at age 20 to 100 years. Data were 
obtained from a questionnaire, reviewed together with 
an investigator at the day of attendance, a physical 
examination, and from blood samples, including DNA 
extraction.
The Copenhagen City Heart Study
The Copenhagen City Heart Study22 24 26 is a prospective 
study of the Danish general population initiated in 1976-
78, with follow-up examinations in 1981-83, 1991-94, 
and 2001-03. Participants were recruited and examined 
exactly as in the Copenhagen General Population Study. 
Baseline was considered the first examination an indi-
vidual received in either 1991-94 or 2001-03, and where 
LDL cholesterol was measured.
Patient involvement
No patients were involved in the design of the study, 
recruitment, or conduct of the study. The outcome mea-
surements were based on public discussion on the topic 
and not directly on informed participant priorities, 
experiences, or preferences. Results will, after scientific 
publication, be disseminated to the public in general.
endpoints
Diagnoses of endpoints according to the World Health 
Organization ICD-8 and ICD-10 codes (international 
classification of diseases, eighth and 10th revisions, 
respectively) were collected from 1977 to 10 November 
2014 by reviewing all hospital admissions and diagno-
ses in the national Danish patient registry and all 
causes of death in the national Danish causes of death 
registry.27 28  Endpoints were defined as: Alzheimer’s 
disease (ICD-8: 290.10; ICD-10: F00, G30), vascular 
dementia (ICD-10: F01), any dementia—that is, Alzhei-
mer’s disease, vascular dementia, and non-specified 
dementia combined (ICD-8: 290; ICD10: F00, F01, F03, 
G30),27 28  and Parkinson’s disease (ICD-8: 342; ICD10: 
G20-G22). In Denmark these diseases are diagnosed by 
specialists in neurology, and a validation with full clin-
ical investigation of the register based dementia diag-
noses has previously been performed, with diagnostic 
validity of the Danish hospital registries considered to 
be high.29  The validity of the register based dementia 
diagnoses was further ensured by the presence of the 
well known association with the apolipoprotein ε4 
allele in the Copenhagen General Population Study.28
Follow-up began at the first inclusion into a study 
and ended with censoring at the date of death, occur-
rence of an event, emigration (n=811), or on 10 Novem-
ber 2014 (corresponding to the end of follow-up for the 
least updated register), whichever came first.
lDl cholesterol and PCsK9
The LDL cholesterol level was calculated using the Frie-
dewald equation if plasma triglyceride levels were ≤4.0 
mmol/L and measured by a direct enzymatic method at 
higher triglyceride concentrations (Thermo Fisher Sci-
entific/Konelab). For the observational classification, 
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we multiplied the plasma LDL cholesterol concentra-
tions by 1.43 in those using cholesterol lowering drugs, 
corresponding to an estimated 30% reduction in LDL 
cholesterol level.30 Use of cholesterol lowering drugs 
was self reported, with more than 97% accounted for by 
statins.
BG Medicine (Waltham, MA) measured plasma 
PCSK9 levels in a subset of participants with a sand-
wich enzyme linked immunosorbent assay using anti-
bodies supplied by Merck (Whitehouse Station, NJ). The 
intra-assay and inter-assay coefficients of variation 
were 6.8% and 12.5%, respectively.
Covariates
Plasma levels of total cholesterol, high density lipopro-
tein (HDL) cholesterol, and triglycerides were measured 
using standard hospital assays. Hypertension was a 
systolic blood pressure ≥140 mm Hg (≥135 mm Hg for 
participants with diabetes), diastolic blood pressure 
≥90 mm Hg (≥85 mm Hg for participants with diabetes), 
and/or the participant used antihypertensive drugs pre-
scribed specifically for hypertension.31 Participants also 
reported on smoking, amount smoked daily, and ages of 
starting and quitting, and we used this information to 
calculate pack years smoked. We coded work and lei-
sure time physical activity as “low” for 0-2 hours mod-
erate activity, “intermediate” for 2-4 hours activity, and 
“high” for more than four hours moderate or vigorous 
activity each week during either work or leisure time. 
Information on alcohol consumption was summarised 
in units weekly (1 unit about 12 g of alcohol). Education 
was recorded as <10, 10 to 12, or ≥13 years of completed 
education. For women, menopausal status was also 
recorded. Missing data on covariates varied from 0 to 
1% for any individual variable. In observational analy-
ses we excluded participants with missing covariates 
on an analysis basis (<1.5% excluded). Participants 
included in genetic analyses had complete data on age, 
sex, genotypes, and endpoints.
genotyping
An ABI PRISM 7900HT Sequence Detection System 
(Applied Biosystems, Foster City, CA) and TaqMan 
based assays were used to genotype for LDL cholesterol 
associated genotypes—that is, PCSK9 R46L (rs11591147), 
R237W (rs148195424), I474V (rs562556), E670G 
(rs505151), and HMGCR (rs17238484). We constructed a 
PCSK9 allele score by summation of number of LDL 
cholesterol lowering alleles; we ordered the HMGCR 
genotype by LDL cholesterol concentration; and the 
combined genotype was the sum of PCSK9 and HMCGR 
LDL cholesterol lowering alleles. Because heterozygos-
ity or homozygosity for the common E670G (rs505151) 
genotype raises LDL cholesterol levels, whereas the 
R46L (rs11591147), R237W (rs148195424), and I474V 
(rs562556) genotypes lowers LDL cholesterol levels 
compared with the population mean, we coded the 
allele score −1 for each LDL cholesterol raising allele 
and 1 for each LDL cholesterol lowering allele, resulting 
in a score of −1, 0 (participants being non-carriers for all 
four PCSK9 genotypes), 1, and 2-4 LDL cholesterol 
 lowering alleles. Some allele groups were combined to 
ensure categories included a sufficient number of par-
ticipants. We used an unweighted score because most 
readers intuitively understand a simple summation of 
alleles; however, as a sensitivity analysis, we also gen-
erated weighted allele scoresfor PCSK9 genotypes and 
PCSK9 and HMGCR genotypes combined.
statistical analyses
Data were analysed using Stata SE 13.1.32 For genotypes, 
we tested a deviation from Hardy-Weinberg equilibrium 
using a Pearson χ2 test. Linear regression examined the 
association between LDL cholesterol and PCSK9 plasma 
levels. This is reported as P for trend. Firstly, to test 
whether a low LDL cholesterol level was associated 
with risk of disease, we categorised participants by 
baseline LDL cholesterol concentrations into categories 
reflecting values recommended for lipid lowering treat-
ment (<1.8 mmol/L, 1.8-2.59 mmol/L, 2.60-3.99 mmol/L) 
compared with a large reference group (≥4.0 mmol/L).15 
As a sensitivity analysis, we also examined this associ-
ation excluding participants using lipid lowering drugs 
and categorising LDL cholesterol levels into fifths. We 
tested the associations between low LDL cholesterol 
level and diseases using Cox regression models 
adjusted for age, sex, year of birth, hypertension, smok-
ing, physical activity, alcohol consumption, education, 
and, for women, menopausal status. Adjustment for 
year of birth was done to accommodate changes in diag-
nostic criteria and treatment over calendar time. To test 
for trends for statistical significance across ordered cat-
egories of low LDL cholesterol levels and genotypes we 
used the non-parametric Cuzick’s extension of a Wil-
coxon rank sum test.
Secondly, we used linear regression to test whether 
genotypes and allele scores were associated with low 
LDL cholesterol levels. Because the distribution of LDL 
cholesterol in the population is slightly skewed towards 
higher concentrations, we performed all analyses on 
log transformed values of LDL cholesterol. For geno-
types to be used as unconfounded instruments in the 
Mendelian randomisation approach, they should not 
be associated with known confounders for disease. To 
test this, we used logistic regression to assess whether 
observational low LDL cholesterol levels or the geno-
types and allele scores were associated with the poten-
tial confounders of age, sex, hypertension, smoking, 
physical activity, alcohol consumption, education, and, 
for women, menopausal status.
Thirdly, to test whether genotypes and allele scores 
were associated with risk of disease we used Cox regres-
sion models adjusted for age, sex, and year of birth.
Fourthly, because genotype is constant throughout 
life, and hence impervious to reverse causation, we car-
ried out instrumental variable analysis to assess the 
potential causal effect of genetically low LDL choles-
terol levels on risk of disease using the user written 
ivreg2 and ivpois commands in Stata.33 34ivpois 
 implements generalised methods of moment condi-
tions equivalent to the multiplicative structural mean 
model using instrumental variables,34  with predicted 
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values of the mean of LDL cholesterol level within each 
genotype score category.35 36 Strength of the instruments 
(that is, the strength of the association of the genotypes 
with LDL cholesterol level) was confirmed by F statistics 
of more than 73 (F>10 is considered acceptable) from 
regressions using ivreg2.18 Power to exclude a causal 
risk ratio of disease at a two sided α of 0.05 and β of 
80% was calculated with an online power calculation 
tool (https://sb452.shinyapps.io/power/) for instrumen-
tal variable analysis in Mendelian randomisation stud-
ies with binary outcomes using the ratio (or Wald) 
method.37
Finally, we conducted summary level Mendelian ran-
domisation analyses,38 firstly using genetic variants in 
PCSK9 and HMGCR combined and secondly using all 
LDL cholesterol lowering genetic variants identified in 
the published genome-wide association study (GWAS) 
Global Lipid Genetics Consortium (n=95 454),20 except 
variants in the APOE gene with numerous well known 
pleotropic effects, and for each LDL cholesterol lowering 
variant estimated risk of Alzheimer’s disease, using the 
International Genomics of Alzheimer’s Project (n=17 008 
Alzheimer’s disease cases and n=37 154 controls).21 The 
second part using all available genetic variants was 
done to increase the generalisability of the study for 
pathways examined, and because none of the PCSK9 
and HMGCR variants in the Global Lipid Genetics Con-
sortium/International Genomics of Alzheimer’s Project 
were associated strongly with LDL cholesterol concen-
trations (see appendix A for information on these study 
populations). In brief, the genetic variants were selected 
from the Global Lipid Genetics Consortium to either be 
located in the PCSK9 (chromosome 1: 55 039 548-
55 064 852) or in the HMGCR (chromosome 5: 75 338 133-
75 344 300) genes or to be associated with low LDL 
cholesterol levels with P values of <1E-7 (960 variants). 
The threshold of <1E-7 was selected to ensure a high 
degree of independence of association between the 
genetic variants and low density lipoprotein cholesterol, 
even with multiple testing.39 In both samples we 
excluded variants with ambiguous information on 
minor allele, effect allele, and direction of the associa-
tion. Also, we excluded variants with ambiguous direc-
tion of the association with LDL cholesterol level among 
laboratories contributing to the Global Lipid Genetics 
Consortium and variants with missing values. We then 
pruned the variants manually for pleiotropy excluding 
variants with reported associations with confounding 
phenotypes using GWAS Central (www.gwascentral.
org/); and for linkage disequilibrium using the SNP 
Annotation and Proxy search (SNAP, www.broadinsti-
tute.org/mpg/snap/), excluding variants in linkage dis-
equilibrium with an R2>0.80, leaving 26 variants from 
the PCSK9 and HMGCR genes (see supplementary 
table 1), and 380 variants using the wider selection crite-
ria (see supplementary table 2). To obtain robust sum-
mary estimates of the causal effect of low LDL cholesterol 
level on risk of Alzheimer’s disease from the summary 
level data, we performed regression analysis using 
inverse variance weighting and Egger Mendelian rando-
misation using the user written mregger command in 
Stata,40 where the inverse variance weighted estimates 
correspond to those obtained using conventional Men-
delian randomisation on individual level data, and 
Egger Mendelian randomisation analysis to estimate a 
causal effect accounting for direct pleiotropic effects of 
the variants, and finally weighted median of instrumen-
tal variable estimates using the user written mrmedian 
command in Stata41  accounting for up to 50% of infor-
mation coming from invalid or weak instruments.40 41
Results
Of 111 194 participants 4087 (3.7%) had LDL cholesterol 
levels of <1.8 mmol/L, 22 335 (18%) of 1.8-2.59 mmol/L, 
57 847 (52%) of 2.6-3.99 mmol/L, and 28 925 (26%) of 
≥4.0 mmol/L. During follow-up, 1001 participants 
developed Alzheimer’s disease, 256 vascular dementia, 
2154 any dementia, and 460 Parkinson’s disease. Partic-
ipants with an LDL cholesterol concentration <1.8 
mmol/L versus ≥4.0 mmol/L were younger, had higher 
HDL cholesterol and lower triglyceride concentrations, 
and were more likely to have been in education for more 
than 13 years (table 1 ). Also, women were more likely to 
be premenopausal. Plasma LDL cholesterol levels were 
directly associated with plasma PCSK9 concentrations 
(P for trend=0.004) and showed a slightly skewed distri-
bution in the population, with a tail towards higher lev-
els (fig 1). PCSK9 R46L (rs11591147), R237W 
(rs148195424), I474V (rs562556), E670G (rs505151), and 
HMGCR (rs17238484) genotype distributions did not 
deviate from Hardy-Weinberg expectations (all P>0.05).
lDl cholesterol and risk of disease: observational 
estimates
Observationally, categories of lower LDL cholesterol 
levels reflecting values recommended for lipid lowering 
treatment (<1.8 mmol/L, 1.8-2.59 mmol/L, 2.6-3.99 
mmol/L) were associated with a stepwise higher risk of 
Parkinson’s disease (P for trend=0.009; Bonferroni cor-
rected for multiple testing P for trend=0.036), but not of 
Alzheimer’s disease, vascular dementia, or any demen-
tia (fig 2). During a median follow-up of 8.2 years (range 
0 to 37), the multifactorially adjusted hazard ratio for 
Parkinson’s disease in those with an LDL cholesterol 
level of <1.8 mmol/L versus ≥4.0 mmol/L was 1.70 (95% 
confidence interval 1.03 to 2.79), whereas the corre-
sponding hazard ratios for Alzheimer’s disease, vascu-
lar dementia, or any dementia did not differ from 1.0. 
These results were similar when participants were cate-
gorised into fifths of LDL cholesterol levels (see supple-
mentary figure 1), and when those using lipid lowering 
drugs were excluded (see supplementary figure 2). The 
association between LDL cholesterol level and risk of 
Parkinson’s disease was not linear and risk was only 
increased at LDL cholesterol levels below 4 mmol/L (see 
supplementary figure 3).
genotypes and plasma lDl cholesterol
An increasing number of PCSK9 and HMGCR alleles 
separately and combined were associated with step-
wise lower mean LDL cholesterol levels (fig 3, left 
panel). Scores of 2-4 versus −1 for PCSK9 LDL  cholesterol 
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lowering alleles was associated with 8.1% lower LDL 
cholesterol levels. The PCSK9 alleles explained 2.7% of 
the variation in LDL cholesterol levels (F statistic=73). 
Scores of 2 versus 0 for HMGCR LDL cholesterol lower-
ing alleles was associated with 3.0% lower LDL choles-
terol levels. The HMGCR alleles explained 0.2% of the 
variation in LDL cholesterol levels (F statistic=90). 
Scores of 4 versus −1 or 0 for PCSK9 and HMGCR LDL 
cholesterol lowering alleles combined was associated 
with 9.3% lower LDL cholesterol levels. The combined 
allele score explained 1.7% of the variation in LDL cho-
lesterol levels (F statistic=73).
Confounding factors
We tested whether potentially confounding factors were 
associated with LDL cholesterol level, disease, and 
genetic variants. Age, sex, hypertension, smoking, 
physical activity, alcohol consumption, educational 
level, and, for women menopausal status were all 
strongly associated with both low LDL cholesterol lev-
els and/or with risk of Alzheimer’s disease, vascular 
dementia, any dementia, and Parkinson’s disease (see 
supplementary figure 4), and may therefore confound 
the observational associations. However, the genotypes 
were not associated with any of the potential confound-
ers, suggesting that pleiotropic effects through any of 
the above factors are not likely.
genotypes and risk of disease: genetic estimates
Age, sex, and year of birth adjusted risks of Alzheimer’s 
disease, vascular dementia, any dementia, and Parkin-
son’s disease were not statistically significantly differ-
ent among participants scores of 2-4 PCSK9 LDL 
cholesterol lowering alleles, 2 HMGCR LDL cholesterol 
lowering alleles, or 4 LDL cholesterol lowering alleles 
combined compared with participants with scores of −1 
or 0 LDL cholesterol lowering alleles (fig 4) (see supple-
mentary table 3 for risk estimates). Using a weighted 
allele score for PCSK9 and alleles combined gave simi-
lar results (see supplementary figure 5). Prevalence of 
dementia and Parkinson’s disease is age dependent; 
however, stratifying analyses by below and above 
age 60 years gave similar results (see supplementary 
figure 6). APOE genotype (positive control) showed the 
known association of the ɛ43 and ɛ44 genotypes with 
risk of Alzheimer’s disease, vascular dementia, and any 
dementia, confirming the validity of the endpoints used 
and study power to show positive associations.
Causal effect of low lDl cholesterol level on risk of 
disease
The hazard ratios for a 1 mmol/L lower observational 
LDL cholesterol level were 0.96 (0.91 to 1.02) for Alzhei-
mer’s disease, 1.09 (0.97 to 1.23) for vascular dementia, 
1.01 (0.97 to 1.06) for any dementia, and 1.10 (1.00 to 
1.21) for Parkinson’s disease (fig 4 ). In genetics, causal 
analyses adjusted for age, sex, and year of birth, risk 
ratios for a 1 mmol/L lower LDL cholesterol level were 
0.57 (95% confidence interval 0.27 to 1.17) for Alzhei-
mer’s disease, 0.81 (0.34 to 1.89) for vascular dementia, 
0.66 (0.34 to 1.26) for any dementia, and 1.02 (0.26 to 
4.00) for Parkinson’s disease (fig 4). Using summary 
level data from the International Genomics of Alzhei-
mer’s Project for 26 variants in the PCSK9 and HMGCR 
genes, the risk ratio for Alzheimer’s disease was 2.04 
(95% confidence interval 0.48 to 12) in an inverse vari-
ance weighted analysis, 0.24 (0.02 to 2.79) using Egger 
Mendelian randomisation analysis, and 4.66 (0.57 to 
38.0) using a weighted median of instrumental variable 
estimates analysis. Corresponding estimates using 380 
table 1 | baseline characteristics of participants by low density lipoprotein (lDl) cholesterol level. values are numbers (percentages) unless stated 
otherwise
Characteristics
lDl cholesterol (mmol/l)
P trend all<1.8 1.8-2.59 2.6-3.99 ≥4.0
Participants 4087 (3.7) 20 335 (18) 57 847 (52) 28 925 (26) 111 194 (100)
Median (interquartile range) age (years) 49 (40-64) 51 (42-64) 56 (47-66) 58 (50-66) <0.001 56 (46-66)
Women 2370 (58) 11 794 (58) 31 237 (54) 15 909 (55) <0.001 61 310 (55)
Median (interquartile range) LDL cholesterol (mmol/L) 1.6 (1.3-1.7) 2.3 (2.1-2.5) 3.2 (2.9-3.6) 4.4 (4.1-4.8) <0.001 3.2 (2.6-3.9)
Median (interquartile range) HDL cholesterol (mmol/L) 1.7 (1.3-2.1) 1.7 (1.3-2.1) 1.6 (1.3-2.0) 1.5 (1.2-1.8) <0.001 1.6 (1.2-1.9)
Median (interquartile range) Triglycerides (mmol/L) 1.1 (0.7-1.8) 1.1 (0.8-1.7) 1.4 (1.0-2.0) 1.7 (1.2-2.4) <0.001 1.4 (1.0-2.1)
Hypertension 695 (17) 2847 (14) 8677 (15) 5207 (18) <0.001 17 426 (16)
Median (interquartile range) smoking, pack years (smokers only) 7.5 (0-27) 4.5 (0-23) 7.5 (0-27) 15 (0-30) <0.001 9.5 (0-28)
Physical activity:
 Low 1717 (42) 8541 (42) 27 188 (47) 15 041 (52) <0.001 52 487 (47)
 Intermediate 1921 (47) 9761 (48) 26 031 (45) 11 859 (41) 0.003 49 572 (44)
 High 450 (11) 2034 (10) 5206 (9) 2025 (7) <0.001 9715 (8)
Median (interquartile range) alcohol consumption (units/week)* 6 (2-13) 6 (2-13) 6 (2-14) 6 (2-14) 0.14 6 (2-14)
Education (years):
 <10 858 (21) 4068 (20) 15040 (26) 9545 (33) <0.001 29 511 (27)
 10-13 2289 (56) 12 210 (60) 34 708 (60) 16 198 (56) <0.001 65 405 (58)
 ≥13 940 (23) 4068 (20) 8099 (14) 3182 (11) <0.001 16 289 (15)
Postmenopausal, women only 450 (19) 2713 (23) 9683 (31) 6205 (39) <0.001 19 051 (31)
HDL=high density lipoprotein.
LDL cholesterol concentration was multiplied by 1.43 in participants receiving cholesterol lowering treatment, corresponding to an estimated 30% reduction in LDL cholesterol levels. Multiply 
by 38.6 to convert cholesterol values from mmol/L to mg/dL.
*1 unit alcohol is about 12 g.
doi: 10.1136/bmj.j1648 | BMJ 2017;357:j1648 | the bmj
RESEARCH
6
genetic variants associated with low LDL cholesterol 
levels according to the Global Lipid Genetics Consor-
tium were 0.83 (0.75 to 0.92), 0.64 (0.52 to 0.79), and 0.97 
(0.91 to 1.02), respectively. Data from the latter analyses 
showed a modest indication of directional pleiotropy 
for genetic variants with low precision, but this bias 
was not correlated with the association of genetic vari-
ants with LDL cholesterol level and the assumptions for 
using Egger regression were not violated (see supple-
mentary figures 7 and 8).
discussion
In 111 194 individuals from the general population, we 
found that low LDL cholesterol levels were associated 
observationally with a high risk of Parkinson’s disease 
but not with Alzheimer’s disease, vascular dementia, or 
any dementia. Low LDL cholesterol levels due to PCSK9 
and HMGCR genetic variants did not appear to increase 
the risk of Alzheimer’s disease, vascular dementia, any 
dementia, or Parkinson’s disease. However, using 
 similar data on 380 genetic variants associated with low 
LDL cholesterol levels, genetically low LDL cholesterol 
was associated with a reduced risk, suggesting a causal 
effect of low LDL cholesterol level in reducing the risk of 
Alzheimer’s disease.
strengths and weaknesses of this study
Strengths of the study include examination of a large 
number of individuals from a homogenous general 
population, access to individual participant data of a 
high validity, no losses to follow-up, and the use of the 
Mendelian randomisation approach. This approach 
allows us to examine potential causal effects of low 
LDL cholesterol on risk of disease, largely without con-
founding and definitely without reverse causation. 
Also, the inclusion of two sample Mendelian randomi-
sation estimates from the Global Lipid Genetics Con-
sortium and the International Genomics of 
Alzheimer’s Project increases the generalisability of 
the results by adding risk estimates obtained from 
people of other ethnicities than white people and of 
low LDL cholesterol levels by more pathways than the 
PCSK9 and HMGCR. Risk of Alzheimer’s disease was 
estimated in data from the International Genomics of 
Alzheimer’s Project using three summary data Mende-
lian randomisation analyses (fig 4 ): the conventional 
inverse variance weighted analysis (unadjusted for 
pleiotropy where a genetic variant is associated with 
more than one phenotype); an analysis using Egger 
Mendelian randomisation, which reduces over-esti-
mation of a causal effect due to pleiotropy, provided 
the gene-exposure (ie, genetically low LDL cholesterol 
levels) does not correlate with the bias due to direc-
tional pleiotropy (the InSIDE assumption), but at the 
cost of lower power; and weighted median of instru-
mental variable estimates analysis accounting for up 
to 50% of information coming from invalid or weak 
instruments.40 41 Risk estimates from these three anal-
yses were all in the same direction, suggesting a causal 
effect of low LDL cholesterol levels in causing a lower 
risk of Alzheimer’s disease.
A weakness is that the estimates obtained in the 
Copenhagen General Population Study and the Copen-
hagen City Heart Study rely on genetic variants from a 
few genes, which means that the causal estimates may 
not apply to mechanisms mediated by other genes; 
however, we carefully selected the genetic variants as 
those associated with the highest effect on LDL choles-
terol levels to reduce risk of weak instruments. The cur-
rent practice in Mendelian randomisation often 
involves a two sample Mendelian randomisation in 
which the causal effect is estimated as the weighted 
average of Wald estimator’s for several genetic variants 
associated with the biomarker of interest—that is, low 
LDL cholesterol levels. It is often argued that this is 
especially powerful since current genome wide associ-
ation study (GWAS) meta-analyses estimate very pre-
cisely the association between a particular genetic 
variant and the biomarker.39 However, we question that 
this is true for our analyses. The GWAS estimates for the 
association between genotype and intermediate pheno-
LDL cholesterol (mmol/L)
A
B
PC
SK
9 
(n
m
ol
/L
)
<1.8
(n=26)
1.8-2.59
(n=115)
2.6-3.99
(n=244)
≥4.0
(n=140)
P for trend = 0.004
0
2
3
4
1
LDL cholesterol (mmol/L)
No
 o
f i
nd
iv
id
ua
ls
 (0
00
s)
0
4
6
8
10
12
2
0 1 2 3 4 5 6 7 8
3.7%
(n=4087)
18%
(n=20 335)
52%
(n=57 847)
26%
(n=28 925)
Fig 1 | (a) Plasma pro-protein convertase kexin-subtilisin 9 
(PCsK9) concentration as a function of categories of low 
density lipoprotein (lDl) cholesterol in 489 participants 
from the Copenhagen general Population study not 
receiving lipid lowering treatment. bands inside boxes 
correspond to medians, bottoms and tops of the boxes to 
interquartile ranges, and whiskers to 10th and 90th 
centiles. P value is for trend across ordered groups from 
linear regression. n=number of participants. (b) 
Distribution of lDl cholesterol levels in general population 
and categories used in the study, reflecting values 
recommended for lipid lowering treatment (<1.8 mmol/l, 
1.8-1.59 mmol/l, 2.6-3.99 mmol/l) compared with large 
reference group (≥4.0 mmol/l). n=number of participants 
in category and percentage of population
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type are derived from many pooled cohorts where 
 phenotype (ie, LDL cholesterol levels) often is mea-
sured using different methods in the various studies. 
Also, genetic variants in GWAS may not be the variants 
with the largest effect on the intermediate phenotype, 
as can be seen for PCSK9 and HMGCR variants in the 
Global Lipid Genetics Consortium/International 
Genomics of Alzheimer’s Project (see supplementary 
table 1). Furthermore, the genotype-phenotype associa-
tion may differ among different ethnicities. In our study 
we used measurements performed at a single labora-
tory and we included around 110 000 white people of 
Danish descent to determine the genotype-phenotype 
association, and we used the same people to study the 
genotype-endpoint association. This might be a much 
more accurate determination than a pooled estimate 
from many different studies and ethnicities. However, 
the estimate obtained using data from the Global Lipid 
Genetics Consortium and International Genomics of 
Alzheimer’s Project studies relies on several genes and 
ethnicities, and showed similar results, suggesting that 
a low LDL cholesterol level in itself is not associated 
with risk.
More cases and controls and thus more statistical 
power would have been ideal to better refute or confirm 
the hypothesis that low LDL cholesterol levels lead to a 
high risk of dementia and Parkinson’s disease, particu-
larly in the Copenhagen studies. As can be seen from 
figure 4, right column, the power to exclude a genetic 
association is limited for some of the endpoints. To bal-
ance this limitation, it is reassuring that within the 
same study population we showed the well known 
causal association between the APOE 4 allele and high 
risk of Alzheimer’s disease. Furthermore, for Alzhei-
mer’s disease the inclusion of the Global Lipid Genetics 
Consortium and International Genomics of Alzheimer’s 
Project studies vastly increased statistical power in the 
genetic studies. Nevertheless, the Copenhagen results 
are important, also because they provide the observa-
tional findings.
Observationally, there was a statistically significant 
trend for a higher risk of Parkinson’s disease across cat-
egories of lower LDL cholesterol levels (P=0.009 for cat-
egories and P=0.001 for fifths), but at most a borderline 
significant association between continuous LDL choles-
terol levels and Parkinson’s disease (hazard ratio for a 1 
mmol/L lower LDL cholesterol level was 1.10 (95% 
 confidence interval 1.00 to 1.21); P=0.05). This differ-
ence is probably because the risk of Parkinson’s disease 
as a function of lower LDL cholesterol levels is not lin-
ear but only present at LDL cholesterol levels below 4.0 
mmol/L.
Other studies
Current guidelines on treatment and prevention of car-
diovascular disease recommend an LDL cholesterol 
level less than 1.8 mmol/L in patients at high cardiovas-
cular risk, and less than 2.6 mmol/L in patients at high 
risk.15  Very low LDL cholesterol levels could therefore 
be of concern, as cholesterol is a major constituent of 
the human brain and as low LDL cholesterol levels in 
theory could lead to dementia and Parkinson’s disease. 
This concern is now even timelier, as novel PCSK9 
inhibitors added to statins can reduce LDL cholesterol 
to very low levels.5 6
Reassuringly, however, extensive studies have 
described a normal neurological phenotype in a woman 
compound heterozygous for loss-of-function mutations 
in PCSK9, with no detectable expression of PCSK9 and 
with extremely low LDL cholesterol levels.42  This obser-
vation is in accordance with the present findings of no 
consistent associations between low LDL cholesterol lev-
els, observationally and genetically, and risk of Alzhei-
mer’s disease, vascular dementia, any dementia, or 
Parkinson’s disease. In contrast with previous stud-
ies10 13 43  we only found an increased observational risk of 
Parkinson’s disease at low levels of LDL cholesterol and 
no increase in risk of dementia. An explanation for this 
could be that previous studies have been cross sectional, 
and severe neurological disease may change dietary 
intake and lifestyle, and thus LDL cholesterol levels. The 
increased observational risk of Parkinson’s disease at 
low LDL cholesterol levels in our study may also be due 
to reverse causation, as preclinical Parkinson’s disease 
may change lifestyle. It can be argued that it is unusual to 
conduct a Mendelian randomisation study when there is 
no observational association, as observed for dementia 
in our study. However, as statistically significant observa-
tional associations have been observed in previous stud-
ies,10 13 43 it nevertheless seems relevant to conduct a 
Mendelian randomisation study. An observational low 
LDL cholesterol level is the net result of our genes, 
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Fig 2 | Prospective risk of alzheimer’s disease, vascular dementia, any dementia, and Parkinson’s 
disease as a function of baseline low density lipoprotein (lDl) cholesterol in categories reflecting 
values recommended for lipid lowering treatment (<1.8 mmol/l, 1.8-1.59 mmol/l, 2.6-3.99 
mmol/l) compared with a large reference group (≥4.0 mmol/l). Multifactorially adjusted for age, 
sex, birth year, smoking (pack years), alcohol (units/week), physical inactivity, income, education, 
and menopause for women. individuals with an event before baseline were excluded. P values are 
for test for trend of hazard ratios across ordered groups. total=number of participants
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dietary intake, use of drugs, and chronic diseases, 
whereas the genetically low LDL cholesterol levels exam-
ined using Mendelian randomisation represent lifelong 
low LDL cholesterol levels through a specific genetic 
pathway only—ie, via PCSK9 or HMGCR.
Early on, PCSK9 was recognised as a potential drug 
target for lowering LDL cholesterol levels,44 45  and effi-
cacy and safety studies have shown that PCSK9 inhi-
bition with monoclonal antibodies results in a 61-62% 
reduction in LDL cholesterol levels with few side 
effects.5 6 14 In long term studies of PCSK9 inhibition, 
neurocognitive events have, however, been reported 
more frequently in people treated with evolocumab 
(0.9% v 0.3%) and alirocumab (1.2% v 0.5%) com-
pared with placebo; although results have not been 
 statistically significant.5 6 14  The neurological symp-
toms reported have been diverse and unspecific, 
including cognitive and attention disorders and dis-
turbances, amnesia, confusion, delirium, dementia, 
and disturbances in thinking and perception; some 
have occurred within 24 hours after onset of treat-
ment; and the observed symptoms had no apparent 
relation to achieved LDL cholesterol concentra-
tions.5 6 14 Furthermore, a Mendelian randomisation 
study using the PCSK9 R46L (rs11591147) variant, as 
also included in the present study, did not find an 
association with impaired cognitive performance or 
functional status in 5777 elderly participants in the 
PROspective Study of Pravastatin in the Elderly at 
Risk (PROSPER).46
For statins, and despite the fact that 2180 million 
prescriptions have been dispensed in the US since 
marketing began in 1987, effects on cognitive function 
remain controversial.7-9 11  However, cognitive related 
adverse events have been reported to the US Food and 
Drug Administration at a rate of 1.9 per 1 million pre-
scriptions, which is similar to rates seen with other 
commonly prescribed cardiovascular drugs.47  Also, an 
exhaustive and systematic review using PubMed, 
Embase, Cochrane Library, and FDA databases con-
cluded that in statin users there appeared to be: no 
increase in the incidence of Alzheimer’s disease; no 
difference in cognitive performance related to proce-
dural memory, attention, or motor speed; no increase 
in incidence of dementia or mild cognitive impair-
ment; and no change in cognitive performance related 
to global cognitive performance scores, executive 
function, declarative memory, processing speed, or 
visuoperception.47  However, another study also using 
FDA databases found that neurological disease was 
reported more often for lipophilic statins that more 
readily cross the blood-brain barrier, than for hydro-
phobic statins.48  A meta-analysis of 23 randomised 
clinical intervention trials on statins reporting data on 
cognitive function in 29 012 participants failed to show 
adverse cognitive effects of statins and thus lower LDL 
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Fig 3 | Prospective risk of alzheimer’s disease, vascular dementia, any dementia, and Parkinson’s disease as a function of PCSK9,HMGCR, and combined 
alleles adjusted for age, sex, and birth year. as a positive control of study power, risk of disease is also shown as a function of APOE ɛ43 and ɛ44 alleles 
compared with the common ɛ33 allele. number of participants may vary owing to availability of genotypes. P values are from tests for trend of hazard 
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cholesterol levels during treatment.13 This meta- 
analysis was specifically designed to meta-analyse 
cognitive test results and adverse event reports from 
randomised clinical intervention trials of statin treat-
ment in cognitively healthy and impaired people in the 
short and long term. Taken together, there is no evi-
dence for an association of low LDL cholesterol levels 
and risk of neurological disease from systematic 
reviews, meta-analysis of large randomised clinical 
intervention trials, and the present Mendelian rando-
misation study.
What the present study adds
Compared with previous observational data prone to 
confounding and reverse causation, and influenced by 
negative and positive stories on statins in the press,49 50 
our results using the Mendelian randomisation 
approach are completely free of reverse causations and 
largely free of confounding. Using such genetic data we 
could not detect any evidence that lifelong low LDL 
cholesterol levels had any harmful effects on risk of 
dementia and Parkinson’s disease. If anything, low LDL 
cholesterol levels may lead to a low risk of Alzheimer’s 
disease.
implications of the present findings
With current recommendation for patients at high risk 
of cardiovascular disease to lower their LDL choles-
terol levels below 1.8 mmol/L, and with conflicting 
reports on risk of neurological diseases in previous 
observational studies on lipid lowering, the finding of 
no causal harmful effect of low LDL cholesterol levels 
on risk of Alzheimer’s disease, vascular dementia, 
any dementia, and Parkinson’s disease is important. 
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Fig 4 | risk of alzheimer’s disease, vascular dementia, any dementia, and Parkinson’s disease for a 1 mmol/l lower 
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However, the present results should not be used to 
predict effects of specific lipid lowering drugs. Strin-
gent cognitive  studies are at present conducted in ran-
domised clinical intervention trials of PCSK9 
inhibitors,5 6 and we await these findings before draw-
ing firm conclusions.
Conclusion and future research
We used genetic variants in PCSK9 and a variant in 
HMGCR, all lowering LDL cholesterol levels, to examine 
the causal effect of low LDL cholesterol levels on risk of 
neurological disease and did not observe any associa-
tions with increased risk of Alzheimer’s disease, vascu-
lar dementia, any dementia, and Parkinson’s disease in 
111 194 people from the general population. Data on 380 
genetic variants from the International Genomics of 
Alzheimer’s Project were, however, suggestive of a 
causal effect of low LDL cholesterol levels in reducing 
the risk of Alzheimer’s disease. Beside randomised clin-
ical intervention trials of PCSK9 inhibitors that are 
ongoing,5 6 Mendelian randomisation studies such as 
the present one, but with more statistical power, are 
needed.
We thank the staff and participants of the Copenhagen General 
Population Study and the Copenhagen City Heart Study; the 
participants of the Global Lipid Genetics Consortium and the 
International Genomics of Alzheimer’s Project for their generous 
participation; and the consortiums for making data publicly available.
Contributors: All authors contributed to the study, data collection, 
interpretation of data, and editing of the paper. MB and AT-H were 
also responsible for data analysis, data summary, drawing of original 
figures, and writing of the manuscript. MB, RFS, ATH, and BGN are the 
guarantors. For the Global Lipid Genetics Consortium and the 
International Genomics of Alzheimer’s Project the investigators 
contributed to the design and implementation of these two specific 
studies and/or provided data, but did not participate in analysis or 
writing of the present study. See supplementary Appendix A for further 
information.
Funding: This study was supported by the Danish Council for 
Independent Research, Medical Sciences; Gentofte and Herlev 
Hospital, Copenhagen University Hospital; and Chief Physician Johan 
Boserup and Lise Boserup’s Fund.
Competing interests: All authors have completed the ICMJE 
uniform disclosure form at www.icmje.org/coi_disclosure.pdf and 
declare: no support from any organisation for the submitted work; 
no financial relationships with any organisation that might have an 
interest in the submitted work in the previous three years; no other 
relationships or activities that could appear to have influenced the 
submitted work.
Ethical approval: Studies were approved by the Herlev and Gentofte 
Hospital and by Danish ethical committees (KF-100.2039/91, 
KF-01-144/01, H-KF-01-144/01). Written informed consent was 
obtained from participants.
Data sharing: No additional data available.
Transparency: The lead author (MB) affirms that the manuscript is an 
honest, accurate, and transparent account of the study being reported; 
that no important aspects of the study have been omitted; that 
discrepancies from the study as planned have been explained, and 
that the paper conforms to transparency policy of the International 
Committee of Medical Journal Editors uniform requirements for 
manuscripts submitted to biomedical journals.
This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on different 
terms, provided the original work is properly cited and the use is 
non-commercial. See: http://creativecommons.org/licenses/
by-nc/4.0/.
1 Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment 
Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive 
lowering of LDL cholesterol: a meta-analysis of data from 170,000 
participants in 26 randomised trials. Lancet 2010;376:1670-81. 
doi:10.1016/S0140-6736(10)61350-5. 
2 O’Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke 
prevention: a meta-analysis involving 121,000 patients. Am J Med 
2008;121:24-33. doi:10.1016/j.amjmed.2007.06.033. 
3 Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment 
Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol 
with statin therapy in people at low risk of vascular disease: 
meta-analysis of individual data from 27 randomised trials. Lancet 
2012;380:581-90. doi:10.1016/S0140-6736(12)60367-5. 
4 Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment 
Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy 
in 18,686 people with diabetes in 14 randomised trials of statins: a 
meta-analysis. Lancet 2008;371:117-25. doi:10.1016/
S0140-6736(08)60104-X. 
5 Sabatine MS, Giugliano RP, Wiviott SD, et al. Open-Label Study of 
Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. 
Efficacy and safety of evolocumab in reducing lipids and 
cardiovascular events. N Engl J Med 2015;372:1500-9. doi:10.1056/
NEJMoa1500858. 
6 Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM 
Investigators. Efficacy and safety of alirocumab in reducing lipids and 
cardiovascular events. N Engl J Med 2015;372:1489-99. doi:10.1056/
NEJMoa1501031. 
7 Strom BL, Schinnar R, Karlawish J, Hennessy S, Teal V, Bilker WB. Statin 
Therapy and Risk of Acute Memory Impairment. JAMA Intern Med 
2015;175:1399-405. doi:10.1001/jamainternmed.2015.2092. 
8 Bernick C, Katz R, Smith NL, et al. Cardiovascular Health Study 
Collaborative Research Group. Statins and cognitive function in the 
elderly: the Cardiovascular Health Study. Neurology 2005;65:1388-
94. doi:10.1212/01.wnl.0000182897.18229.ec. 
9 Evans MA, Golomb BA. Statin-associated adverse cognitive effects: 
survey results from 171 patients. Pharmacotherapy 2009;29:800-11. 
doi:10.1592/phco.29.7.800. 
10 Huang X, Alonso A, Guo X, et al. Statins, plasma cholesterol, and risk 
of Parkinson’s disease: a prospective study. Mov Disord 2015;30:552-
9. doi:10.1002/mds.26152. 
11 Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive 
function in the elderly. Results of the PROSPER study. J Neurol 
2010;257:85-90. doi:10.1007/s00415-009-5271-7. 
12 Bai S, Song Y, Huang X, et al. Statin Use and the Risk of Parkinson’s 
Disease: An Updated Meta-Analysis. PLoS One 2016;11:e0152564. 
doi:10.1371/journal.pone.0152564. 
13 Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A 
systematic review and meta-analysis of randomized controlled trials. J 
Gen Intern Med 2015;30:348-58. doi:10.1007/s11606-014-3115-3. 
14 Giugliano RP, Sabatine MS. Are PCSK9 Inhibitors the Next 
Breakthrough in the Cardiovascular Field?J Am Coll Cardiol 
2015;65:2638-51. doi:10.1016/j.jacc.2015.05.001. 
15 Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members. 
2016 European Guidelines on cardiovascular disease prevention in 
clinical practice: The Sixth Joint Task Force of the European Society of 
Cardiology and Other Societies on Cardiovascular Disease Prevention 
in Clinical Practice (constituted by representatives of 10 societies and 
by invited experts)Developed with the special contribution of the 
European Association for Cardiovascular Prevention & Rehabilitation 
(EACPR). Eur Heart J 2016;37:2315-81. doi:10.1093/eurheartj/ehw106. 
16 Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. DIAGRAM Consortium 
MAGIC Consortium InterAct Consortium. HMG-coenzyme A reductase 
inhibition, type 2 diabetes, and bodyweight: evidence from genetic 
analysis and randomised trials. Lancet 2015;385:351-61. 
doi:10.1016/S0140-6736(14)61183-1. 
17 Stender S, Tybjærg-Hansen A. Using human genetics to predict the 
effects and side-effects of drugs. Curr Opin Lipidol 2016;27:105-11. 
doi:10.1097/MOL.0000000000000280. 
18 Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. 
Mendelian randomization: using genes as instruments for making 
causal inferences in epidemiology. Stat Med 2008;27:1133-63. 
doi:10.1002/sim.3034. 
19 Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic 
epidemiology contribute to understanding environmental 
determinants of disease?Int J Epidemiol 2003;32:1-22. doi:10.1093/
ije/dyg070. 
20 Willer CJ, Schmidt EM, Sengupta S, et al. Global Lipids Genetics 
Consortium. Discovery and refinement of loci associated with lipid 
levels. Nat Genet 2013;45:1274-83. doi:10.1038/ng.2797. 
21 Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. European Alzheimer’s 
Disease Initiative (EADI) Genetic and Environmental Risk in Alzheimer’s 
Disease Alzheimer’s Disease Genetic Consortium Cohorts for Heart 
and Aging Research in Genomic Epidemiology. Meta-analysis of 
74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s 
disease. Nat Genet 2013;45:1452-8. doi:10.1038/ng.2802. 
22 Stender S, Nordestgaard BG, Tybjaerg-Hansen A. Elevated body mass 
index as a causal risk factor for symptomatic gallstone disease: a 
Mendelian randomization study. Hepatology 2013;58:2133-41. 
doi:10.1002/hep.26563. 
RESEARCH
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
23 Nordestgaard BG, Palmer TM, Benn M, et al. The effect of elevated 
body mass index on ischemic heart disease risk: causal estimates 
from a Mendelian randomisation approach. PLoS Med 
2012;9:e1001212. doi:10.1371/journal.pmed.1001212. 
24 Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Elevated 
remnant cholesterol causes both low-grade inflammation and 
ischemic heart disease, whereas elevated low-density lipoprotein 
cholesterol causes ischemic heart disease without inflammation. 
Circulation 2013;128:1298-309. doi:10.1161/
CIRCULATIONAHA.113.003008. 
25 Benn M, Tybjærg-Hansen A, Smith GD, Nordestgaard BG. High body 
mass index and cancer risk-a Mendelian randomisation study. Eur J 
Epidemiol 2016;31:879-92. doi:10.1007/s10654-016-0147-5. 
26 Nordestgaard BG, Palmer TM, Benn M, et al. The effect of elevated 
body mass index on ischemic heart disease risk: causal estimates 
from a Mendelian randomisation approach. PLoS Med 
2012;9:e1001212. doi:10.1371/journal.pmed.1001212. 
27 Frikke-Schmidt R, Nordestgaard BG, Thudium D, Moes Grønholdt ML, 
Tybjaerg-Hansen A. APOE genotype predicts AD and other dementia 
but not ischemic cerebrovascular disease. Neurology 2001;56:194-
200. doi:10.1212/WNL.56.2.194. 
28 Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt 
R. Plasma levels of apolipoprotein E and risk of dementia in the 
general population. Ann Neurol 2015;77:301-11. doi:10.1002/
ana.24326. 
29 Phung TK, Andersen BB, Høgh P, Kessing LV, Mortensen PB, Waldemar 
G. Validity of dementia diagnoses in the Danish hospital registers. 
Dement Geriatr Cogn Disord 2007;24:220-8. 
doi:10.1159/000107084. 
30 Jones PH, Davidson MH, Stein EA, et al. STELLAR Study Group. 
Comparison of the efficacy and safety of rosuvastatin versus 
atorvastatin, simvastatin, and pravastatin across doses (STELLAR* 
Trial). Am J Cardiol 2003;92:152-60. doi:10.1016/
S0002-9149(03)00530-7. 
31 Whitworth JA. World Health Organization, International Society of 
Hypertension Writing Group. 2003 World Health Organization (WHO)/
International Society of Hypertension (ISH) statement on 
management of hypertension. J Hypertens 2003;21:1983-92. 
doi:10.1097/00004872-200311000-00002. 
32  Stata Statistical Software. Release 13.StataCorp LP, 2013.
33 Baum C, Schaffer M, Stillman S. Instrumental variables and GMM: 
Estimation and testing. Stata J 2003;3:1-31.
34 Nichols A. Ivpois: Stata module for IV/GMM Poisson regression. Stata/
SE 13 1. 2007 http://ideas.repec.org/c/boc/bocode/s456890.html
35 Instrumental variables and GMM: estimation and testing. Stata J 
2003;3:1-33.
36 Didelez V, Meng S, Sheehan NA. Assumptions of IV Methods for 
Observational Epidemiology. Stat Sci 
2010;25:22-40doi:10.1214/09-STS316.
37 Burgess S. Sample size and power calculations in Mendelian 
randomization with a single instrumental variable and a binary 
outcome. Int J Epidemiol 2014;43:922-9. doi:10.1093/ije/dyu005. 
38 Burgess S, Butterworth A, Thompson SG. Mendelian randomization 
analysis with multiple genetic variants using summarized data. Genet 
Epidemiol 2013;37:658-65. doi:10.1002/gepi.21758. 
39 Panagiotou OA, Ioannidis JP. Genome-Wide Significance Project. What 
should the genome-wide significance threshold be? Empirical 
replication of borderline genetic associations. Int J Epidemiol 
2012;41:273-86. doi:10.1093/ije/dyr178. 
40 Bowden J, Davey Smith G, Burgess S. Mendelian randomization with 
invalid instruments: effect estimation and bias detection through 
Egger regression. Int J Epidemiol 2015;44:512-25. doi:10.1093/ije/
dyv080. 
41 Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent 
Estimation in Mendelian Randomization with Some Invalid 
Instruments Using a Weighted Median Estimator. Genet Epidemiol 
2016;40:304-14. doi:10.1002/gepi.21965. 
42 Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization 
of loss-of-function mutations in PCSK9 and identification of a 
compound heterozygote. Am J Hum Genet 2006;79:514-23. 
doi:10.1086/507488. 
43 Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total 
cholesterol and the risk of Parkinson disease. Neurology 
2008;70:1972-9. doi:10.1212/01.wnl.0000312511.62699.a8. 
44 Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause 
autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-
6. doi:10.1038/ng1161. 
45 Cohen JC, Boerwinkle E, Mosley TH Jr,, Hobbs HH. Sequence variations 
in PCSK9, low LDL, and protection against coronary heart disease. N 
Engl J Med 2006;354:1264-72. doi:10.1056/NEJMoa054013. 
46 Postmus I, Trompet S, de Craen AJ, et al. PCSK9 SNP rs11591147 is 
associated with low cholesterol levels but not with cognitive 
performance or noncardiovascular clinical events in an elderly 
population. J Lipid Res 2013;54:561-6. doi:10.1194/jlr.M033969. 
47 Richardson K, Schoen M, French B, et al. Statins and cognitive 
function: a systematic review. Ann Intern Med 2013;159:688-97. 
doi:10.7326/0003-4819-159-10-201311190-00007. 
48 Sahebzamani FM, Munro CL, Marroquin OC, Diamond DM, Keller E, Kip 
KE. Examination of the FDA Warning for Statins and Cognitive 
Dysfunction. J Pharmacovigil 2014;2:e1000141
doi:10.4172/2329-6887.1000141.
49 Nielsen SF, Nordestgaard BG. Negative statin-related news stories 
decrease statin persistence and increase myocardial infarction and 
cardiovascular mortality: a nationwide prospective cohort study. Eur 
Heart J 2016;37:908-16. doi:10.1093/eurheartj/ehv641. 
50 Matthews A, Herrett E, Gasparrini A, et al. Impact of statin related media 
coverage on use of statins: interrupted time series analysis with UK 
primary care data. BMJ 2016;353:i3283. doi:10.1136/bmj.i3283. 
Supplementary figure: Mendelian randomisation 
study design
Supplementary information: additional tables and 
figures
